Optimal dosing of a novel PLK4 inhibitor nested in a phase II study of CFI-400945 in patients with Advanced/Metastatic Breast Cancer (MBC): Canadian Cancer Trials Group (CCTG) IND.237. (October 2022) - Rushton, M.; Cescon, D.; Hilton, J.; Bedard, P.; Blanchette, P.; Bashir, A.; Pezo, R.; Kumar, V.; Ng, T.; Awan, A.; Lott, A.; Raphael, J.A.; et al.